FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
As reported in the Journal of Clinical Oncology, Maurer et al have developed FLIPI24, a modern prognostic model for newly diagnosed follicular lymphoma.
As stated by the investigators, “Although most patients with … [follicular lymphoma] can expect an indolent course, progressive lymphoma remains...
Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers
In a UK study reported in the Journal of Clinical Oncology, Gandhi et al found that whereas breast cancer incidence was reduced with bilateral risk-reducing mastectomy (BRRM) among women carrying BRCA1/BRCA2 pathogenic variants, no difference vs surveillance was observed in breast cancer–specific...
CLL/SLL: FDA Approves Combination of Acalabrutinib and Venetoclax
On February 19, the U.S. Food and Drug Administration (FDA) approved the Bruton’s tyrosine kinase inhibitor acalabrutinib (Calquence) tablets and capsules in combination with the BCL2 inhibitor venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma...
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
In an individual patient data meta-analysis (WOLVERINE) reported in The Lancet Oncology, Tang et al found that the addition of metastasis-directed therapy (MDT) to standard of care (SOC) was associated with benefits in patients with oligometastatic prostate cancer.
Study Details
A systematic review ...
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
Researchers developed a deep neural network, M-PACT, to identify and classify brain tumors in pediatric patients from the subnanogram-input cell-free DNA of methylomes, according to findings published in Nature Cancer.
“This is a next-generation assay and computational framework that we’ve...
Stage II Melanoma: Adjuvant Pembrolizumab and Risk of New Skin Cancers
The incidence of new primary melanoma was similar among patients with completely resected stage IIB or IIC cutaneous melanoma who did vs did not receive adjuvant pembrolizumab, while nonmelanoma skin cancers were more common with placebo, according to a secondary analysis of the multicenter phase...
Long-Term Survival Results With Addition of Adjuvant mFOLFOX6 to Hepatectomy in Patients With Liver Metastases From Colorectal Cancer
As reported in the Journal of Clinical Oncology by Kanemitsu et al, long-term results of the Japanese phase II/III JCOG0603 trial showed that the addition of adjuvant mFOLFOX6 to hepatectomy did not improve overall survival vs hepatectomy alone in patients with liver-only metastases from colorectal ...
Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO
New research highlighting the growing potential of radiopharmaceutical therapies (RPT) to improve outcomes for people with cancer was presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium, which took place in Palm Desert, California, and online on February 17 and 18....
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Treatment with the novel CD123-targeting antibody-drug conjugate pivekimab sunirine led to a high rate of complete and durable responses in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially among patients being treated in the front-line setting. The antibody-drug...
Genetics Pioneer Zsofia K. Stadler, MD, to Lead JCO Precision Oncology
Zsofia K. Stadler, MD, has been appointed as the next Editor-in-Chief of JCO Precision Oncology (JCO PO), an ASCO journal. JCO PO is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and...
Does Diabetes Increase Pancreatic Cystic Neoplasm Risk?
Longer duration of diabetes is associated with a modestly increased risk of developing pancreatic cystic neoplasms, based on the results of a Korean nationwide population-based cohort study published in JAMA Network Open. Cho et al noted that the association was more pronounced among younger...
Topline Progression-Free Survival Results From BREAKWATER in Metastatic Colorectal Cancer Newly Announced
Pfizer has announced positive topline progression-free survival results from cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating encorafenib in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated...
Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer
The addition of the BRAF inhibitor encorafenib and the EGFR antibody cetuximab to chemotherapy with FOLFIRI (leucovorin, fluorouracil, and irinotecan) in the first-line treatment of BRAF V600E–mutated metastatic colorectal cancer led to a significant improvement in overall response rate—compared...
Pleurectomy/Decortication Safe in Select Patients With Pleural Mesothelioma
Pleurectomy/decortication can be completed safely in select patients with pleural mesothelioma with low postoperative mortality, according to findings from a study published in The Annals of Thoracic Surgery.
“Our findings show that pleurectomy/decortication can be done safely when patients are...
Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening
Repeated methodological flaws in published research result in misinformation that may cause eligible patients to forgo or not be offered lung cancer screening, according to a joint publication from the Society of Thoracic Surgeons (STS), American Society for Radiation Oncology (ASTRO), and American ...
Chemoradiation Plus Atezolizumab in Limited-Stage Small Cell Lung Cancer
As reported in the Journal of Clinical Oncology by Higgins et al, the phase III NRG Oncology/Alliance LU005 trial showed no overall survival benefit with the addition of atezolizumab to concurrent chemoradiation (CRT) in patients with limited-stage small cell lung cancer (LS-SCLC).
Study Details
In ...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Ultra-Hypofractionated vs Conventionally Fractionated RT for Localized Prostate Cancer—10-Year Outcomes
As reported in The Lancet Oncology by Nilsson et al, the 10-year analysis of the phase III HYPO-RT-PC trial confirmed the noninferiority of ultra-hypofractionated vs conventionally fractionated radiotherapy (RT) in failure-free survival in patients with localized prostate cancer.
The previously...
Can a Game-Based Intervention Reduce Cardiovascular Risk in Minority Cancer Survivors?
A remotely delivered, behaviorally designed game-based intervention was found to increase physical activity and may have implications for cardiovascular health among Black and Hispanic breast and prostate cancer survivors with cardiovascular risk factors compared with attention control, according...
Colorectal Cancer: How Does Lifetime Alcohol Consumption Affect Risk?
Studies have demonstrated a link between alcohol consumption and an elevated risk of colorectal cancer. New research now reveals that higher lifetime alcohol consumption is also associated with a higher risk, especially for rectal cancer, and that quitting drinking can lower a person’s risk. The...
New Report Shows Colorectal Cancer Is Top Cause of Cancer Mortality in Those Under 50
A new study by American Cancer Society (ACS) researchers shows that overall cancer mortality in people younger than age 50 in the United States has decreased by 44%, from 25.5 per 100,000 people in 1990 to 14.2 in 2023. The progress is due to declines in mortality for four of the five leading...
Can Color Vision Deficiency Impact Survival in Bladder or Colorectal Cancer?
Color vision deficiency is an inherited condition affecting 1 in 12 males (8%) and 1 in 200 females (0.5%), most often impairing the ability to distinguish the color red. A recent study published in Nature Health examined the possible impact of color vision deficiency on survival outcomes among...
Cancer Surgery Outcomes Similar Between Rural and Urban Facilities
Patients in rural areas who received surgery locally for their lung or colon cancer had comparable surgical outcomes and mortality rates to patients who underwent surgery in an urban facility, according to the results of an analysis published in the Journal of the American College of Surgeons.
...
Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma
In a prospective, longitudinal cohort study published in JACC: CardioOncology by Glen et al, cancer therapy–related cardiac dysfunction and hypertension were found to be common cardiovascular adverse events among patients with melanoma who received BRAF or MEK inhibitor therapy.
Nearly half...
COMMIT: First-Line Atezolizumab Plus FOLFOX and Bevacizumab Regimen in Metastatic Colorectal Cancer
In the phase III COMMIT trial, a regimen combining atezolizumab plus bevacizumab and standard chemotherapy significantly improved progression-free survival and response rates over atezolizumab monotherapy in patients with previously untreated mismatch repair deficient (dMMR) or microsatellite...
Computational Histology Artificial Intelligence–Powered Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer
In a study reported in the Journal of Clinical Oncology, Hendifar et al found that a computational histology artificial intelligence (CHAI)-powered platform could be used to identify whether gemcitabine-based (G-chemo) or fluoropyrimidine-based (F-chemo) chemotherapy is preferred as first-line...
FDA Approves Once-Monthly Dosing Schedule for Amivantamab and Hyaluronidase-lpuj
Today, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro). When administered in combination with oral lazertinib for the first-line treatment EGFR-mutated...
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer
In a meta-analysis reported in JAMA Oncology, Zaorsky et al found that longer durations of androgen-deprivation therapy given with definitive radiotherapy were associated with nonlinear relative benefits in patients with localized prostate cancer.
Study Details
The meta-analysis used...
Induction Nivolumab Before CRT in High-Risk HPV-Driven Oropharyngeal Cancer
In a French phase II trial (IMMUNEBOOST-HPV) reported in the Journal of Clinical Oncology, Mirghani et al found that use of induction nivolumab prior to chemoradiation (CRT) did not meet the endpoint of ‘receipt of full treatment in due time’ (FTDT) in patients with high-risk human papillomavirus...
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in HER2-Positive Breast Cancer
In a Chinese phase III trial (neoCARHP) reported in the Journal of Clinical Oncology, Gao et al found that neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) was noninferior in pathologic complete response (pCR) compared with THP plus carboplatin (TCbHP) in patients with stage...
Nonmetastatic Breast Cancer: Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors
Aromatase inhibitors are a cornerstone of adjuvant therapy for hormone receptor–positive breast cancer, significantly reducing recurrence and mortality. However, by suppressing estrogen production, aromatase inhibitors can accelerate bone loss and increase fracture risk. To counter this,...
ASH Guidelines on Management of Newly Diagnosed and Relapsed/Refractory ALL in AYA Patients
The American Society of Hematology (ASH) released guidelines on front-line management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population. Both guidelines, grounded in evidence-based practice,...
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid
The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing datasets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma.
...
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Treatment with a single injection of an oncolytic virus induces persistent T cell–mediated immunity in glioblastoma, according to findings from a trial published in Cell.
“Patients with glioblastoma have not benefited from immunotherapies that have transformed patient care in other cancer types...
Adjuvant Durvalumab in Resected Early-Stage NSCLC
In a phase III trial (Canadian Cancer Trials Group BR.31) reported in the Journal of Clinical Oncology, Goss et al found that adjuvant durvalumab did not improve disease-free survival vs placebo in patients with completely resected early-stage non–small cell lung cancer (NSCLC).
Study Details
In ...
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
The U.S. Food and Drug Administration (FDA) has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs. Specifically, risk statements related to cardiovascular disease, breast cancer, ...
Young-Onset Pancreatic Cancer: Can Alcohol Consumption Raise Risk?
In a nationwide Korean cohort study reported in the Journal of Clinical Oncology, Park et al found that risk of young-onset pancreatic cancer was associated with increased consumption of alcohol and increased frequency of alcohol consumption.
Study Details
In the study, a nationwide cohort of...
ASCO and Conexiant Launch ASCO AI in Oncology
The American Society of Clinical Oncology (ASCO®) and Conexiant today announced the launch of ASCO AI in Oncology, a premier digital destination designed to help oncology professionals navigate the transformative role of artificial intelligence (AI) in cancer care. Launching this initiative marks...
Demographic and Clinicopathologic Factors in Colorectal Adenoma Recurrence Risk
As reported in JAMA Network Open by Awan et al, both histopathologic and demographic factors show distinct time-dependent associations with colorectal adenoma recurrence in postpolypectomy surveillance.
In this retrospective cohort study, high-grade dysplasia demonstrated the strongest association ...
ASH Publishes Clinical Guidelines on AL Amyloidosis Diagnosis
The American Society of Hematology (ASH) has released clinical practice guidelines on the diagnosis of light chain (AL) amyloidosis, which were published in Blood Advances. Additionally, the expert panel behind the guidelines also published a scoping review about the clinical features of systemic...
FDA Approves TTFields Device for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, noninvasive device that delivers alternating electrical fields, known as tumor treating...
Interval Cancer Rate With AI-Supported Mammography Screening
In a Swedish trial (MASAI) reported in The Lancet, Gommers et al found that artificial intelligence (AI)-supported mammography was noninferior to standard double reading without AI in identifying interval breast cancers in women undergoing breast cancer screening.
Study Details
In the study,...
COA Survey Shows Insurer Utilization Management Interferes With Cancer Treatment Decisions
A national survey of independent community oncology practices has found that utilization management tactics imposed by health insurers and pharmacy benefit managers (PBMs) delay cancer treatment, interfere with physician-directed care, and increase administrative and financial burdens on practices...
PSMA PET/CT-Guided Radiotherapy After Prostatectomy
New research published by Nikitas et al in JNCCN—Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) scans may be able to predict progression-free survival...
Rural Populations Face Greater Barriers as Nonmedical Costs Hinder Cancer Clinical Trial Access
Earlier this week, 25 health-care organizations proposed that the Health and Human Services Office of Inspector General adopt a new regulatory safe harbor from the Anti-Kickback Statute that would allow clinical trial sponsors to financially support patients to offset indirect or nonmedical costs...
FDA Approves Pembrolizumab With Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
On February 10, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian,...
A New Risk Model for Esophagectomy Draws on the STS National Database
A nationwide, real-world analysis using the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) from 2012 to 2023 evaluated over 16,000 adults who underwent esophagectomy for primary esophageal cancer to develop and validate a long-term all-cause mortality risk model. The...
Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA
As reported in the Journal of Clinical Oncology by Tung et al, findings in expansion cohorts of the phase II Translational Breast Cancer Research Consortium (TBCRC) 048 study showed that olaparib was active in patients with metastatic breast cancer with germline PALB2 mutations (gPALB2m) and in...
Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors
In an Indian single-center phase III trial (DELII) reported in the Journal of Clinical Oncology, Noronha et al found that “ultra–low-dose” immune checkpoint inhibitor therapy with the PD-1 inhibitor nivolumab was associated with improved overall survival vs standard chemotherapy among patients with ...
Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors
In a phase III single-blind randomized clinical trial reported in JAMA Network Open, Zick et al found that self-acupressure—taught via a mobile app—provided a safe, low-cost approach for managing fatigue in ovarian cancer survivors.
“In this randomized clinical trial, true self-acupressure and...
HPV Testing During Cervical Cancer Screening: Potential ‘Convenient and Noninvasive’ Method
Testing menstrual blood for human papillomavirus (HPV) could be a “robust alternative or replacement” for current cervical cancer screening by a clinician, according to findings from a Chinese study published by Tian et al in The BMJ.
The researchers say using menstrual blood for HPV testing is...
Guidelines Harmonize Pan-Tumor Pathologic Response to Neoadjuvant Therapy
The first unified, pan-tumor guideline framework has been released for how pathologists should evaluate and score response in the neoadjuvant setting. These consensus guidelines, which were a joint effort by the Society for Immunotherapy of Cancer's (SITC) Pan-tumor Harmonization of Pathologic...
Tissue-Free ctDNA and Outcomes in Patients With Colorectal Cancer Receiving FOLFOX-Based Adjuvant Therapy
In a study reported in the Journal of Clinical Oncology, Sinicrope et al found that a tissue-free circulating tumor DNA (ctDNA) assay had strong prognostic value in patients receiving FOLFOX (fluorouracil, leucovorin, and oxaliplatin)-based adjuvant therapy for stage III colorectal cancer.
Study...
Ultraprocessed Food Associated With Increased Mortality Risk in Cancer Survivors
Consumption of higher quantities of ultraprocessed food was associated with increased all-cause and cancer mortality rates in cancer survivors, irrespective of the quality of their diet, according to findings published in Cancer Epidemiology, Biomarkers & Prevention.
“These results suggest...
A Paradigm Shift In Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
Breakthrough research presented at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting shows that additional lymph node evaluation is needed during surgery for non–small cell lung cancer (NSCLC) to accurately identify cancer spread (Abstract A-1588).
Globally, surgical standards vary on the ...
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Willems et al, venous thromboembolism (VTE) occurred in a high proportion of patients with resectable/borderline resectable pancreatic ductal adenocarcinoma receiving neoadjuvant FOLFOXIRI (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin)...
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
Exposure to Agent Orange in U.S. veterans was associated with an increased odds of developing acral melanoma compared with controls with and without cutaneous melanoma, according to findings published in JAMA Dermatology.
The study authors suggested that there is a need for continued...
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
The U.S. Food and Drug Administration (FDA) has provided communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil—indicated for colorectal, breast, gastric/esophageal/gastroesophageal, and pancreatic cancers—related to risks associated...
Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
Initial results from the phase III GIMEMA ALL2820 trial demonstrated that a front-line, chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed a standard treatment strategy of imatinib plus...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
Metastasis-Directed Therapy for Oligometastatic Prostate Cancer
Metastasis-directed therapy significantly improved progression-free survival, radiologic progression–free survival, and castration resistance–free survival in patients with oligometastatic prostate cancer, according to a new study published by Tang et al in The Lancet Oncology.
The study is a...
New European Project Cluster EARLYSCAN Launched to Advance Early Detection of Heritable Cancers
A new European collaboration cluster, EARLYSCAN (Early Screening & Hereditary Cancer Awareness Network), has been launched to strengthen prevention and early detection strategies for heritable cancers. The cluster brings together three Horizon Europe–funded projects: SHIELD, DISARM, and
First-Line mFOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Conca et al, the final results of the Italian phase III TRIPLETE trial showed that first-line mFOLFOXIRI (modified fluorouracil, leucovorin, oxaliplatin, irinotecan) plus panitumumab improved overall survival vs mFOLFOX (modified fluorouracil,...
WHO Analysis Finds Nearly 40% of Global Cancer Cases Attributable to Modifiable Risk Factors
Almost 40% of all new cancer cases could be attributed to at least one of 30 modifiable risk factors, according to a new global analysis from the World Health Organization (WHO) and its International Agency for Research on Cancer (IARC). The analysis of preventable cancers was published in Nature...
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
In a phase III trial (PATINA) reported in The New England Journal of Medicine, Metzger et al found that the addition of palbociclib to anti-HER2 and endocrine therapies significantly prolonged progression-free survival in patients with hormone receptor–positive, HER2-positive metastatic breast...
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care.
Now in its second year, the World...
American College of Surgeons Publishes Annual NCDB Report
The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in neoadjuvant treatments, such as chemotherapy, immunotherapy, and hormone therapy, often allowing for less invasive surgery and helping clinicians assess how a...
New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and is most often diagnosed at advanced, unresectable stages, when 5-year survival is just 3%.
The results from two retrospective phase II studies investigating blood biomarkers to detect early-stage pancreatic ductal...
AI Tool May Predict Cardiac Events in Patients With Cancer and Acute Coronary Syndrome
An artificial intelligence (AI)-based risk prediction model, ONCO-ACS, showed possible favorable clinical utility as a practical tool for predicting cardiovascular death, myocardial infarction, and ischemic stroke events in patients with cancer and acute coronary syndrome, according to findings...
Overall Survival With 3 vs 6 Months of Adjuvant Oxaliplatin Plus Fluoropyrimidine for Colorectal Cancer
As reported in the Journal of Clinical Oncology by Iveson et al, final results of the UK-based noninferiority phase III SCOT trial have shown noninferiority of 3 vs 6 months of adjuvant oxaliplatin plus fluoropyrimidine chemotherapy in overall survival among patients with colorectal cancer....
Adjuvant Aumolertinib in EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhang et al, the Chinese phase III ARTS trial showed superior disease-free survival with the third-generation EGFR tyrosine kinase inhibitor aumolertinib as adjuvant therapy vs placebo in patients with completely resected stage II to IIIB EGFR-mutated non–small ...
Deep-Learning CT Biomarker Predicts Survival Better Than Traditional Measures in Immunotherapy-Treated Advanced NSCLC
Sako et al conducted a prognostic study to evaluate whether a fully automated deep-learning radiomic biomarker based on serial CT scans could improve prediction of overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. Their findings,...
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
Randomized Trial Shows AI-Supported Mammography Improves Sensitivity and Lowers Interval Cancer Rate
A randomized, controlled clinical trial for artificial intelligence (AI)–supported mammography readings, called the MASAI trial, demonstrated that AI reads of mammogram scans led to fewer interval breast cancer diagnoses than with standard double reads by radiologists, according to findings...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy.
Findings from the De-Squamate study were published in the...
Head and Neck Cancer: How Does Genetic Ancestry Impact Tumor Genomics?
Genetic ancestry plays a key role in determining the behavior of head and neck tumors and may help explain why African American patients survive for half as long as their counterparts of European ancestry, according to a new review study published by Ndahayo et al in Cancer and Metastasis Reviews.
...
CRI Launches Open Database for Immunotherapy Cancer Research
The Cancer Research Institute (CRI) in collaboration with 10x Genomics, Stanford University School of Medicine, the University of Pennsylvania Perelman School of Medicine, and Memorial Sloan Kettering Cancer Center, has launched an open foundational database for cancer immunotherapy research. The
Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25%
A team of researchers and physicians found that utilizing ultrasound-guided diffuse optical tomography (DOT) technology may reduce unnecessary breast biopsy rates by nearly 25%. Using this new method first—rather than starting with a biopsy—may help to determine if additional diagnoses are needed...
AACR Announces Fellows of the AACR Academy Class of 2026
The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy.
The Fellows of the AACR Academy was established to honor scientists, clinicians, and physician-scientists whose visionary work has reshaped the landscape of cancer...
Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer
In a cohort study analysis reported in the Journal of Clinical Oncology, Valenza et al found that extended endocrine therapy after 5 years of adjuvant luteinizing hormone–releasing hormone agonist (LHRHa) treatment was associated with benefit among premenopausal women with node-positive, hormone...
Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus, Esophageal Cancer
The Spray Cryotherapy Esophageal Consortium has developed a set of expert and evidence-based consensus recommendations guiding the use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. The recommendations, decided upon through a modified Delphi process, were...
Machine Learning–Enhanced Prognostic Scoring Predicts Survival and Classifies Risk From Spinal Metastases
A prognostic scoring system for predicting 1-year survival in patients with advanced cancer and spinal metastases was enhanced with machine learning for greater accuracy, according to the results of a Japanese multicenter study published in Spine.
"This model provides a practical risk assessment...
Comprehensive Multiomic Resource for HPV-Negative Head and Neck Cancers
In a comprehensive molecular characterization of the most common type of head and neck cancer, researchers from the United States and Poland have clarified the contribution of key cancer-associated genes, proteins, and signaling pathways in these cancers, while proposing possible new treatment...
Emergency Department Use and Unplanned Hospitalization Among Patients With Head and Neck Cancer: Association With Reported Symptom Burden
In a Canadian population-based study reported in the Journal of Clinical Oncology, Noel et al found that patient-reported symptom burden was significantly associated with the likelihood of emergency department use and unplanned hospitalization among patients with head and neck cancer.
Study...
Reduced-Dose Intensity-Modulated Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma
In the phase II NRG Oncology HN002 trial reported in the Journal of Clinical Oncology, Sue S. Yom, MD, PhD, and colleagues found that a reduced-dose intensity-modulated radiation therapy (IMRT) regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma satisfied...
Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that endoscopic nasopharyngectomy was associated with improved overall survival vs intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent nasopharyngeal carcinoma who had received prior...
FDA Pipeline: Designations in Ovarian, Head/Neck, and Thyroid Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a novel immunotherapy for the treatment of ovarian cancer as well as Breakthrough Therapy designation to treatments for HRAS-mutant head and neck squamous cell carcinoma and previously treated thyroid cancer....
FDA Pipeline: Novel Treatments in Lymphoma, Nasopharyngeal Cancer, Solid Tumors, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents for several kinds of lymphoma, as well as nasopharyngeal cancer; a Breakthrough Therapy designation for a treatment for patients with NTRK-positive advanced solid tumors; and Fast Track designation for...
First-Line TPEx vs EXTREME Regimen for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In a phase II trial (GORTEC 2014-01 TPExtreme) reported in The Lancet Oncology, Joël Guigay, MD, and colleagues found that first-line TPEx (docetaxel/platinum/cetuximab) did not improve overall survival vs the standard-of-care EXTREME regimen (fluorouracil [5-FU]/platinum/cetuximab) in patients...
FDA Pipeline: Reviews for Agents in Acute Graft-vs-Host Disease, Nasopharyngeal and Ovarian Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to an agent for the prevention of acute graft-vs-host disease; Breakthrough Therapy designation to an anti–PD-1 monoclonal antibody for the treatment of metastatic nasopharyngeal carcinoma; and Fast Track designation to a ...
Tipifarnib for Patients With Advanced HRAS-Mutant Head and Neck Cancer and High Variant Allele Frequency
In a phase II trial reported in the Journal of Clinical Oncology, Ho et al found that tipifarnib produced a high response rate among patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations and high variant allele frequency.
As stated by the investigators,...
First-Line Cisplatin Plus Gemcitabine or Fluorouracil for Advanced Nasopharyngeal Carcinoma: Final Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Hong et al, the final overall survival analysis of the Chinese phase III GEM20110714 trial showed a significant benefit with gemcitabine/cisplatin vs fluorouracil/cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal...
Addition of Avelumab to Chemoradiotherapy in Previously Untreated Patients With Locally Advanced Head and Neck Cancer
As reported in The Lancet Oncology by Nancy Y. Lee, MD, and colleagues, the phase III JAVELIN Head and Neck 100 trial showed no improvement in progression-free survival with the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy in patients with previously untreated locally advanced...
Meta-analysis of Treatment Modalities for Locally Advanced Head and Neck Cancer
In an individual patient data network meta-analysis reported in The Lancet Oncology, Petit et al identified treatment modalities associated with improved overall survival vs locoregional treatment alone in nonmetastatic head and neck squamous cell cancer, with hyperfractionated radiotherapy and...
Sentinel Lymph Node Biopsy–Navigated vs Elective Neck Dissection for Early Oral Cancer
In a Japanese noninferiority phase III trial reported in the Journal of Clinical Oncology, Hasegawa et al found noninferior survival and improved neck functionality with sentinel lymph node biopsy (SLNB)-navigated neck dissection vs elective neck dissection in patients with previously untreated...
New Research Finds Few Young Adult Men Have Received the HPV Vaccine
Using data from the 2010–2018 National Health Interview Surveys, Chen et al found that just 16% of men who were 18 to 21 years old had received at least one dose of the human papillomavirus (HPV) vaccine at any age. In comparison, 42% of women in the same age bracket had gotten at least one shot of ...
Pembrolizumab Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
In a cohort of a phase II trial reported in The Lancet Oncology, Assuntina G. Sacco, MD, and colleagues found that the combination of pembrolizumab and cetuximab produced durable responses in patients with recurrent or metastatic head and neck squamous cell carcinoma who had received no prior PD-1, ...
